CD157抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using CD157 mouse mAb against Rat spleen (1) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CD157 mouse mAb (green) and negative control (red).    

  
  

CD157. also known as BST-1 (bone marrow stromal cell antigen-1), is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the ADP-ribosyl cyclase family, which includes CD38. Initially identified in bone marrow stromal cells, CD157 plays roles in immune regulation, cell adhesion, and signaling. It functions both as an ectoenzyme, catalyzing NAD metabolism, and as a receptor involved in leukocyte migration and inflammation. CD157 is expressed on myeloid cells, endothelial cells, and certain cancer cells, and its dysregulation has been linked to autoimmune diseases (e.g., rheumatoid arthritis) and malignancies (e.g., leukemia, ovarian cancer).

CD157 antibodies are critical tools for studying its biological functions and clinical relevance. They enable detection of CD157 expression in tissues or cell lines, aiding in disease diagnosis and prognosis. In research, anti-CD157 antibodies help elucidate mechanisms of leukocyte trafficking, stromal cell interactions, and NAD-mediated signaling. Therapeutically, CD157-targeting antibodies are explored for immune modulation, particularly in cancers where CD157 overexpression correlates with metastasis or chemoresistance. Challenges remain in understanding its dual enzymatic/receptor roles and tissue-specific effects. Recent studies also highlight CD157’s potential as a biomarker for minimal residual disease monitoring in hematologic malignancies. However, its interplay with CD38 and broader NAD metabolome warrants further investigation to optimize antibody-based applications.